WINNIPEG, Manitoba — December 10, 2025 — Leads & Copy — Health Canada has approved Kane Biotech Inc.’s revyve® Antimicrobial Wound Gel Spray for use in Canada. This follows previous clearance of the spray under the FDA 510(k) process in the United States.
The Health Canada approval marks a regulatory achievement for Kane Biotech, reflecting its commitment to advancing wound care innovation in Canada.
The revyve Antimicrobial Wound Gel Spray supports clinicians in managing complex wounds by reducing microbial burden and promoting a healthier wound environment.
According to the company, the approval provides clinicians and patients in Canada with a new option for managing burns, large surface area wounds, and ulcers. The spray is part of Kane Biotech’s revyve wound care portfolio, which has been evaluated in multiple clinical settings in the United States.
Dr. Robert B. Huizinga, Interim CEO of Kane Biotech, stated that the Health Canada approval is a step forward in the company’s mission to improve outcomes for patients with chronic and hard-to-heal wounds, while validating the strength of their clinical data and providing healthcare providers with a new tool to address wound infections.
The company will work with healthcare partners and distributors to ensure access and education regarding the use of the spray.
Kane Biotech is also advancing its wound care portfolio, including the recent FDA submission of revyve Antimicrobial Wound and Skin Cleanser.
Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms contribute to antibiotic resistance in wounds, which can result in serious clinical outcomes and significant cost. The company says that revyve addresses both biofilms and wound bacteria. The revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are US FDA 510(k) cleared and revyve Antimicrobial Wound Gel is Health Canada approved.
Dr. Robert Huizinga
Interim CEO
Kane Biotech Inc.
rhuizinga@kanebiotech.com
(780) 970-1100
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
rdupuis@kanebiotech.com
(204) 298-2200
Source: Kane Biotech Inc.
